Researchers are rapidly investigating retatrutide, a novel medication from Eli Lilly, as a possible breakthrough in weight reduction . Different than many previous approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, substances that influence appetite and blood glucose